PDF factsheet
      Z

statins in cardiovascular prevention for primary prevention, clinical trials results

fluvastatin versus placebo
BCAPS, 2001
fluvastatin 40 mg once daily
versus
placebo
subjects who had carotid plaque but no symptoms of carotid artery diseasedouble-blind
Follow-up duration: 3.0 years
Sweden
pravastatin versus control
FAST Fukuoka pravastatin, 2002
pravastatin 10 mg/day
versus
control group (diet alone)
asymptomatic hypercholesterolemic patients open
Follow-up duration: 2 years
Japan
MEGA, 2006
NCT00211705
pravastatin 10 mg daily (20 mg per day if the total cholesterolconcentration did not decrease to 5·69 mmol/L or less)
versus
control
patients with hypercholesterolaemia (total cholesterol 5·69–6·98 mmol/L) and no history of coronary heart disease or strokeopen, blind assessment
Follow-up duration: 5.3 y
Japan
pravastatin versus placebo
CAIUS, 1996
pravastatin 40mg/d
versus
placebo
asymptomatic patients with hypercholesterolemia and at least one 1.3 < IMT < 3.5 mm in the carotid arteriesdouble blind
Follow-up duration: 3 years
Italy
PMSG, 1993
pravastatin 20 mg once daily
versus
placebo
patients with hypercholesterolemia(serum total cholesterol concentrations of 5.2 to 7.8 mmol/liter) and > or = 2 additional risk factors for atherosclerotic coronary artery diseasedouble blind
Follow-up duration: 26 weeks
PROSPER (primary prevention subgroup), 2002
pravastatin 40mg/d
versus
placebo
men and women aged 70-82 years with a history of, or risk factors for, vascular disease; primary prevention subgroup double blind
Follow-up duration: 3.2 years
Ecosse, Irelande, Pays bas
WOSCOPS, 1995
pravastatine 40 mg daily
versus
placebo
men aged 45-64 yr with no history of myocardial infarction and with raised plasma cholesterol levels (LDL cholesterol of at least 155 mg/dL, total cholesterol of at least 252 mg/dL) double blind
Follow-up duration: 4.9 years
Scotland
pravastatin versus usual care
KLIS, 2000
pravastatin 10-20 mg/day
versus
conventional treatment
Japanese men aged 45-74 years with serum total cholesterol of > or = 220 mg/dl (5.69 mmol/l), primary prevenionopen
Follow-up duration: 5 years
Japan
rosuvastatin versus placebo
HOPE 3, 2016
NCT00468923
rosuvastatin 10 mg per day
versus
placebo
subjects who did not have cardiovascular disease and were at intermediate riskdouble-blind
Follow-up duration: 5.6 years
21 countries
JUPITER, 2008
NCT00239681
rosuvastatin 20 mg daily
versus
placebo
apparently healthy individuals with low LDL-cholesterol levels of less than 130 mg per deciliter but elevated C-reactive-protein (high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher)double blind
Follow-up duration: median 1.9 year
26 countries

  Options


in first

in second

  Filter